The companies will bring together data, software and tuned models to create custom, purpose-built solutions across the drug development lifecycle.
“Next-generation, first-of-its-kind AI model optimization will be a critical foundation in our efforts to shape the future of drug development for pharma and the many patients waiting for innovative treatments,” said Paul Hudson, CEO of Sanofi. a statement.
The drugmaker said it will leverage this collaboration to provide access to proprietary data to develop AI models as it looks to become the first biopharma company driven by AI on a large scale.
OpenAI will contribute to access to cutting-edge AI capabilities, including the ability to improve models, deep AI expertise, and dedicated idea partnerships and resources.
“AI has enormous potential for accelerating drug development,” said Brad Lightcap, COO of OpenAI. “We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market. "
Additionally, the French drugmaker noted that Formation Bio will provide extensive engineering resources, experience operating between pharma and AI, and its tech-driven development platform to design, develop AI technologies across all aspects of the pharma lifecycle.
“By creating and implementing customized AI agents and models designed for their industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the speed at which we bring new medicines to patients. provide," said Benjamin Liu, Co-Founder and CEO, Formation Bio.
“Next-generation, first-of-its-kind AI model optimization will be a critical foundation in our efforts to shape the future of drug development for pharma and the many patients waiting for innovative treatments,” said Paul Hudson, CEO of Sanofi. a statement.
The drugmaker said it will leverage this collaboration to provide access to proprietary data to develop AI models as it looks to become the first biopharma company driven by AI on a large scale.
OpenAI will contribute to access to cutting-edge AI capabilities, including the ability to improve models, deep AI expertise, and dedicated idea partnerships and resources.
“AI has enormous potential for accelerating drug development,” said Brad Lightcap, COO of OpenAI. “We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market. "
Additionally, the French drugmaker noted that Formation Bio will provide extensive engineering resources, experience operating between pharma and AI, and its tech-driven development platform to design, develop AI technologies across all aspects of the pharma lifecycle.
“By creating and implementing customized AI agents and models designed for their industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the speed at which we bring new medicines to patients. provide," said Benjamin Liu, Co-Founder and CEO, Formation Bio.
